Celltrion reveals Remsima clinical trial result on Crohn’s disease at DDW symposium

Published: 2017-05-12 11:53:59

Updated: 2017-05-12 11:53:59

At the U.S. Digestive Disease Week(DDW) symposium at Chicago from the 6^th to 9^th of May, Celltrion revealed a result of the Remsima clinical trial(CT-P12 2.4 CD) on active Crohn’s disease patients and a result of the observational study on a large number of inflammatory bowel disease adult and pediatric patients.

Infliximab, a Remsima’s main substance, is usually prescribed not only to rheumat...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.